Protein Misfolding
| Category | Mechanisms |
|---|---|
| Also known as | misfolded protein, proteopathy |
| Last updated | 2026-04-14 |
| Reading time | 3 min read |
| Tags | mechanismproteostasisprotein-biology |
Overview
Protein misfolding occurs when a protein fails to reach or maintain its native three-dimensional structure, instead adopting conformations that are biologically inactive, aberrantly active, or prone to aggregation. Because protein function depends on precise spatial geometry, misfolded proteins can lose their normal role (loss of function) and/or acquire toxic gain-of-function properties — forming aggregates that damage cellular machinery, sequester other proteins, and ultimately trigger cell death.
Misfolding can arise during synthesis, after post-translational modification, during trafficking, or in response to cellular stress. Cells devote enormous resources to preventing, detecting, and correcting misfolding through a network collectively called proteostasis. Key components include chaperone proteins that assist folding, the ubiquitin-proteasome system and autophagy that degrade misfolded proteins, and stress response pathways such as the unfolded protein response that adjust capacity when demand rises.
Failure of these systems produces "protein misfolding diseases," a class that includes Alzheimer disease (amyloid beta, tau), Parkinson disease (alpha-synuclein), Huntington disease (polyglutamine huntingtin), prion diseases, cystic fibrosis (CFTR delta-F508), type 2 diabetes (islet amyloid polypeptide), and many more. These diseases share mechanistic themes despite distinct clinical presentations.
Mechanism / Process
-
Initial synthesis. Proteins emerge from the ribosome as extended polypeptides that must fold rapidly into functional structures. Chaperones (Hsp70, Hsp90, TRiC/CCT) protect nascent chains from premature aggregation.
-
Folding and quality control. In the endoplasmic reticulum or cytoplasm, quality-control systems check folding fidelity. Properly folded proteins proceed; misfolded ones are retained for correction or degradation.
-
Triggers of misfolding. Mutations, oxidative stress, elevated temperature, pH changes, chaperone overload, or aging can push proteins into misfolded conformations.
-
Aggregation. Misfolded proteins expose normally buried hydrophobic residues, driving aberrant intermolecular interactions. Oligomers may be particularly toxic, while mature amyloid fibrils can be partially inert reservoirs.
-
Cellular responses. Cells attempt to refold (via chaperones), degrade (via proteasome or autophagy), or sequester (in aggresomes or stress granules) misfolded proteins. Sustained misfolding activates stress responses that reduce translation and enhance chaperone synthesis.
-
Failure and disease. When stress responses fail, aggregates persist and damage cells through multiple mechanisms: sequestering critical proteins, overwhelming degradation machinery, disrupting membranes, and generating reactive oxygen species.
-
Spreading. Certain misfolded proteins — notably prions, alpha-synuclein, and tau — can template misfolding of native proteins and spread between cells in a prion-like manner.
Key Players / Molecular Components
- Chaperones. Hsp70, Hsp90, Hsp60, small HSPs, TRiC/CCT.
- Co-chaperones and folding factors. Hsp40 family (J-proteins), BAG proteins, Hop, Cdc37.
- Quality control. ERAD, calnexin/calreticulin cycle, ER-resident chaperones (BiP, PDI).
- Degradation machinery. Proteasome, autophagy, lysosomal proteases.
- Stress responses. Unfolded protein response, heat shock response, integrated stress response.
- Disease-associated proteins. Amyloid-beta, tau, alpha-synuclein, polyQ huntingtin, SOD1, TDP-43, prion protein, transthyretin.
Clinical Relevance / Therapeutic Targeting
Therapies for protein misfolding diseases target several intervention points: chaperone activation (arimoclomol, CFTR correctors like lumacaftor), aggregation prevention (tafamidis for transthyretin amyloidosis, antibody therapies for Alzheimer), enhancement of proteasomal or autophagic clearance, and gene-level strategies (antisense oligonucleotides for Huntington and other polyQ diseases). The field of small-molecule pharmacological chaperones aims to stabilize specific mutant proteins, restoring folding and function. Prion-like spread is a growing therapeutic target for neurodegeneration.
Peptides That Target This Pathway
- Cerebrolysin — peptide preparation studied for neurodegenerative applications.
- Selank — short peptide investigated for neuroprotective effects under stress.
- Semax — ACTH-derived peptide studied for cognitive and neuroprotective effects.
- Epitalon — pineal peptide proposed to affect aging-related proteostasis.
- Humanin — mitochondrial-derived peptide with reported cytoprotective effects.
Related Topics
Related entries
- Autophagy— Autophagy is the cellular self-degradation process by which cells recycle damaged organelles, misfolded proteins, and intracellular pathogens through lysosomal digestion, playing essential roles in quality control, stress adaptation, and longevity.
- Chaperone Proteins— Proteins that assist the folding, refolding, assembly, and degradation of other proteins, protecting cells from misfolding-associated damage.
- Ubiquitin-Proteasome System— The ubiquitin-proteasome system is the cell's principal route for selective protein degradation, marking substrates with ubiquitin chains and breaking them down in the 26S proteasome.
- Unfolded Protein Response— The unfolded protein response is an adaptive network of three ER-resident sensors that rebalances protein folding capacity under stress — and commits cells to death if stress is unresolved.